DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ultravate (Halobetasol Propionate Topical) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

ULTRAVATE SUMMARY

Ultravate®
(halobetasol propionate ointment) Ointment, 0.05%

Ultravate® (halobetasol propionate ointment) Ointment, 0.05% contains halobetasol propionate, a synthetic corticosteroid for topical dermatological use. The corticosteroids constitute a class of primarily synthetic steroids used topically as an anti-inflammatory and antipruritic agent.

Ultravate Ointment 0.05% is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in children under 12 years of age is not recommended.

As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.


See all Ultravate indications & dosage >>

ULTRAVATE NEWS HIGHLIGHTS

Published Studies Related to Ultravate (Halobetasol Topical)

Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. [1998.09]

Double-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses. [1991.12]

A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. [1991.12]

A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. [1991.12]

Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. [1991.12]

more >>

Clinical Trials Related to Ultravate (Halobetasol Topical)

Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis [Not yet recruiting]

more >>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008